ArticleFrontiers in oncology2026

A real-world 10-year follow-up analysis of survival and safety of CD20-targeted therapy in patients with Waldenstrom macroglobulinemia.

Hengming Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.